Alembic Pharmaceuticals Ltd.

Financial

	Alembic Pharma	Ipca Laboratories	JB Chem & Pharma
Operational Metrics
API Sector
US DMF Filings	132.0 .	55.0 .	n/a
Pharmaceutical Sector
Number of ANDA's Filed in Europe	21.0	n/a	n/a
Number of ANDA's Approved in Europe	19.0	n/a	n/a
Number of ANDA's Filed in Canada	21.0	n/a	n/a
Number of ANDA's Approved by Canada	20.0	n/a	n/a
Number of ANDA's Filed in Australia	17.0	n/a	n/a
Number of ANDA's Approved by Australia	14.0	n/a	n/a
Number of ANDA's Filed in USA	257.0 .	44.0 .	19.0 .
Number of ANDA's Approved By USFDA	196.0 .	18.0 .	17.0 .
Number of ANDA's Filed in Latam	14.0	n/a	n/a
Number of ANDA's Approved by Latam	4.0	n/a	n/a
Number of ANDA's Filed in South Africa	21.0	n/a	n/a
Number of ANDA's Approved by South Africa	7.0	n/a	n/a
R&D as a % of Total Sales	7.0 %	2.71 %	1.55 %
Financials
5 yr Average ROE	17.53 %	15.9 %	18.27 %
5yr average Equity Multiplier	1.58	1.41	1.5
5yr Average Asset Turnover Ratio	0.79	0.81	0.79
5yr Avg Net Profit Margin	14.0 %	13.8 %	15.59 %
Price to Book	4.36	5.52	10.65
P/E	32.99	60.18	56.27
5yr Avg Cash Conversion Cycle	11.4 Days	74.74 Days	37.72 Days
Inventory Days	92.17 Days	100.02 Days	52.43 Days
Days Receivable	59.84 Days	55.52 Days	63.16 Days
Days Payable	198.11 Days	120.62 Days	81.2 Days
5yr Average Interest Coverage Ratio	42.05	59.4	74.05
5yr Avg ROCE	19.16 %	18.97 %	22.31 %
5yr Avg Operating Profit Margin	21.64 %	22.38 %	24.93 %
5 yr average Debt to Equity	0.27	0.14	0.06
5yr CAGR Net Profit	-10.16 %	1.13 %	16.2 %
5yr Average Return on Assets	10.9 %	11.44 %	12.35 %
Shareholdings
Promoter Holding	69.61 %	46.3 %	53.78 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	0.13 %	0.01 %	-2.13 %
Change in Mutual Fund Holding (3 Yrs)	3.48 %	7.98 %	4.89 %

Business

	Alembic Pharma	Ipca Laboratories	JB Chem & Pharma
Product Wise Break-Up	Product Wise Break-Up Formulations 82.28 Active Pharmaceutical Ingredient (API) 17.72 Generics 0 Branded Generics 0 Contract Manufacturing 0 Formulation exported 0 Domestic formulation 0	Product Wise Break-Up Branded Generics 54.13 Formulation exported 0 Domestic formulation 0 Contract Manufacturing 0 Formulations 21.36 Formulations 0 Active Pharmaceutical Ingredient (API) 0 Others 24.51	Product Wise Break-Up Branded Generics 0 Formulations 31.36 Domestic Formulations 54.67 Contract Manufacturing 10.53 Generics 0 Formulations 0 Active Pharmaceutical Ingredient (API) 0 Others 3.44
Product Wise Break-Up	Product Wise Break-Up Formulations 82.28 Active Pharmaceutical Ingredient (API) 17.72 Generics 0 Branded Generics 0 Contract Manufacturing 0 Formulation exported 0 Domestic formulation 0	Product Wise Break-Up Branded Generics 54.13 Formulation exported 0 Domestic formulation 0 Contract Manufacturing 0 Formulations 21.36 Formulations 0 Active Pharmaceutical Ingredient (API) 0 Others 24.51	Product Wise Break-Up Branded Generics 0 Formulations 31.36 Domestic Formulations 54.67 Contract Manufacturing 10.53 Generics 0 Formulations 0 Active Pharmaceutical Ingredient (API) 0 Others 3.44
Location Wise Break-Up	Location Wise Break-Up Rest of the World 59.07 India 40.93 Australia 0 CIS 0 Asia 0 USA 0 Africa 0 Europe 0 Russia 0 South Africa 0	Location Wise Break-Up India 52.01 Africa 7.68 South Africa 0 Australia 4.47 Asia Pacific 7.87 Europe 14.15 CIS 3.56 Russia 0 Rest of the World 0 USA 10.26	Location Wise Break-Up India 52.06 Africa 0 South Africa 0 Australia 0 Asia 0 Europe 0 CIS 0 Russia 0 Rest of the World 47.94 USA 0
Therapeutic Area Break-Up	Therapeutic Area Break-Up Nutraceuticals 0 Urology 0 Dermatology 0 Cough 0 Neuro 0 GI 0 Anti Malarials 0 Cardiovascular & Anti Diabetics 0 NSAID 0 Others 100	Therapeutic Area Break-Up Urology 0 Anti Malarials 24.0 Cough 2.0 Nutraceuticals 0 GI 6.0 Cardiovascular & Anti Diabetics 25.0 Dermatology 0 Neuro 7.0 NSAID 21.0 Others 15.0	-

Alembic Pharmaceuticals Ltd.

Alembic Pharmaceuticals Ltd.

SIGN UP FOR FREE